FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
For a step-by-step technique, see standard patient education materials
Methycobalamin B12: Methylcobalamin is the most bio-available type of Vitamin B12 which means the body absorbs it more easily
[DOI] [PubMed] [Google Scholar] 16.Ippolito C., Segnani C., Errede M., Virgintino D., Colucci R., Fornai M., Antonioli L., Blandizzi C., Dolfi A., Bernardini N
Hanne Christensen: Nothing to disclose
There is a large discrepancy between studies that focus on urban experiments and those that explicitly address the learning processes in these experiments
